BPC-157 vs KPV at a glance
| Compared | BPC-157 | KPV |
|---|---|---|
| What it is | 15-amino-acid fragment of a stomach protein | 3-amino-acid fragment of alpha-MSH |
| Main research focus | Tendon, muscle and gut healing | Gut and skin inflammation |
| How it’s said to work | Blood vessel growth and repair signals | Blocks the inflammatory switch NF-κB |
| Human evidence | Three tiny pilot studies | None |
| Status | Not approved; FDA committee backed compounding (July 2026) | Not approved; FDA committee backed compounding (July 2026) |
How are BPC-157 and KPV different?
BPC-157 is said to speed up repair, mainly by helping new blood vessels grow at an injury. KPV is said to calm inflammation by blocking a signal inside cells that switches on inflammatory chemicals.
Both are researched for the gut, from different angles: repair for BPC-157, inflammation for KPV.
What does the research show for each?
BPC-157 has many animal studies, mostly from one group in Croatia, and three small human pilot studies; a 2025 review said it shouldn’t be used clinically until proper trials are done. KPV reduced colitis in mice, with no human trials.
How do the risks compare?
The side effects of both in people are unknown because neither has been properly tested. Researchers have raised theoretical concerns about BPC-157’s effect on blood vessel growth, and products sold online aren’t checked for purity.
Are BPC-157 and KPV legal?
Neither is approved for human use. Both moved off the FDA’s list of compounding substances with safety concerns, and in July 2026 an FDA advisory committee recommended allowing both in pharmacy compounding, which the FDA hasn’t decided on yet.